Patents by Inventor David Paul Fairlie

David Paul Fairlie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Immunological reagents and uses therefor
    Patent number: 10245262
    Abstract: The present invention provides ligands which bind to MR1, some of which induce MR1 to bind to MAIT cells thereby activating or inhibiting MAIT cell activation.
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: April 2, 2019
    Assignees: The University of Queensland, Monash University, The University of Melbourne
    Inventors: Alexandra Jane Corbett, James McCluskey, Lars Kjer-Nielsen, Zhenjun Chen, Jamie Rossjohn, Onisha Patel, Richard William Birkinshaw, Sidonia Barbara Guiomar Eckle, David Paul Fairlie, Ligong Liu, Jeffrey Yam Wing Mak
  • Immunological reagents and uses therefor
    Patent number: 10011602
    Abstract: The present invention provides a ligand which binds to MR1 wherein said binding results in binding of the MR1 to MAIT cells.
    Type: Grant
    Filed: July 5, 2013
    Date of Patent: July 3, 2018
    Assignee: THE UNIVERSITY OF MELBOURNE
    Inventors: Lars Kjer-Nielsen, James McCluskey, Alexandra Corbett, Jamie Rossjohn, Patel Onisha, David Paul Fairlie, Ligong Liu
  • IMMUNOLOGICAL REAGENTS AND USES THEREFOR
    Publication number: 20170209442
    Abstract: The present invention provides ligands which bind to MR1, some of which induce MR1 to bind to MAIT cells thereby activating or inhibiting MAIT cell activation.
    Type: Application
    Filed: April 1, 2015
    Publication date: July 27, 2017
    Inventors: Alexandra Jane Corbett, James McCluskey, Lars Kjer-Nielsen, Zhenjun Chen, Jamie Rossjohn, Onisha Patel, Richard William Birkinshaw, Sidonia Barbara Guiomar Eckle, David Paul Fairlie, Ligong Liu, Jeffrey Yam Wing Mak
  • Modulators of protease activated receptors
    Patent number: 9701711
    Abstract: The present application provides novel compounds of the Formula (I), pharmaceutical compositions comprising such compounds and methods for using such compounds as tools for biological studies or as agents or drugs for modulating Protease Activated Receptor-2 (PAR2) and for treating a subject at risk of—or susceptible to—a disease or disorder, or having a disease or disorder associated with undesirable PAR2 activity.
    Type: Grant
    Filed: October 21, 2014
    Date of Patent: July 11, 2017
    Assignee: The University of Queensland
    Inventors: David Paul Fairlie, Ligong Liu, Mei Kwan Yau, Jacky Yung Suen, Robert Reid
  • IMMUNOLOGICAL REAGENTS AND USES THEREFOR
    Publication number: 20150166542
    Abstract: The present invention provides a ligand which binds to MR1 wherein said binding results in binding of the MR1 to MAIT cells.
    Type: Application
    Filed: July 5, 2013
    Publication date: June 18, 2015
    Applicant: THE UNIVERSITY OF MELBOURNE
    Inventors: Lars Kjer-Nielsen, James McCluskey, Alexandra Corbett, Jamie Rossjohn, Patel Onisha, David Paul Fairlie, Ligong Liu
  • MODULATORS OF PROTEASE ACTIVATED RECEPTORS
    Publication number: 20150038402
    Abstract: The present application provides novel compounds of the Formula (I), pharmaceutical compositions comprising such compounds and methods for using such compounds as tools for biological studies or as agents or drugs for modulating Protease Activated Receptor-2 (PAR2) and for treating a subject at risk of—or susceptible to—a disease or disorder, or having a disease or disorder associated with undesirable PAR2 activity.
    Type: Application
    Filed: October 21, 2014
    Publication date: February 5, 2015
    Inventors: DAVID PAUL FAIRLIE, LIGONG LIU, MEI KWAN YAU, JACKY YUNG SUEN, ROBERT REID
  • Modulations of protease activated receptors
    Patent number: 8927503
    Abstract: The present invention provides novel compounds of the Formula (1), pharmaceutical compositions comprising such compounds and methods for using such compounds as tools for biological studies or as agents or drugs for modulating Protease Activated Receptor-2 (PAR2) and for treating a subject at risk of—or susceptible to—a disease or disorder, or having a disease or disorder associated with undesirable PAR2 activity.
    Type: Grant
    Filed: July 28, 2011
    Date of Patent: January 6, 2015
    Assignee: The University of Queensland
    Inventors: David Paul Fairlie, Ligong Liu, Mei Kwan Yau, Jacky Yung Suen, Robert Reid
  • Modulations of protease activated receptors
    Patent number: 8901085
    Abstract: The present invention provides novel compounds of the Formula (1), pharmaceutical compositions comprising such compounds and methods for using such compounds as tools for biological studies or as agents or drugs for modulating Protease Activated Receptor-2 (PAR2) and for treating a subject at risk of—or susceptible to—a disease or disorder, or having a disease or disorder associated with undesirable PAR2 activity.
    Type: Grant
    Filed: July 28, 2011
    Date of Patent: December 2, 2014
    Assignee: The University of Queensland
    Inventors: David Paul Fairlie, Ligong Liu, Mei Kwan Yau, Jacky Yung Suen, Robert Reid
  • MODULATIONS OF PROTEASE ACTIVATED RECEPTORS
    Publication number: 20130184226
    Abstract: The present invention provides novel compounds of the Formula (1), pharmaceutical compositions comprising such compounds and methods for using such compounds as tools for biological studies or as agents or drugs for modulating Protease Activated Receptor-2 (PAR2) and for treating a subject at risk of—or susceptible to—a disease or disorder, or having a disease or disorder associated with undesirable PAR2 activity.
    Type: Application
    Filed: July 28, 2011
    Publication date: July 18, 2013
    Applicant: THE UNIVERSITY OF QUEENSLAND
    Inventors: David Paul Fairlie, Ligong Liu, Mei Kwan Yau, Jacky Yung Suen
  • Novel methods and compositions for the treatment or prevention of dysmenorrhoea and menstrual side effects: the use of phospholipase inhibitors
    Publication number: 20040247639
    Abstract: The present invention discloses the use of phospholipases A2 inhibitors in compositions and in methods for the treatment and/or prophylaxis of dysmenorrhoea, menstrual migraine and menorrhagia.
    Type: Application
    Filed: June 29, 2004
    Publication date: December 9, 2004
    Inventors: Ian Alexander Shiels, Stephen Maxwell Taylor, David Paul Fairlie